Thursday 27 May 2021

BioLargo (BLGO) Discusses Elimination of Convertible Debt and Progress on Commercialization of PFAS Treatment Technology with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - May 27, 2021) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), a company that invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. President and CEO of BioLargo, Dennis P. Calvert, joined Stock Day host Everett Jolly for an interview.

Jolly began the interview by commenting on the company's latest announcements, including a recent press release detailing the elimination of almost all of the company's convertible debt. "We took quite a bit of risk [three years ago]; we needed that capital and we have put it to great work. We have advanced two platform technologies that are now at a commercial-ready stage, they're dramatic and they have a big future," said Calvert. "The opportunities that are coming to us are so big and so expansive, and it's really a tribute to our great technology and to our people."

"We really needed to get that convertible debt out of the way," continued Calvert, noting that the company's debt peaked at $7.6 million in 2018. "Since then, we have retired all [but $50,000] of this convertible debt, which has been continuing to put pressure on the stock. So, it's a great moment."

Jolly then commented on the company's recent revenues and growth. "I think we're just scratching the surface," said Calvert. "We have put a couple of really key relationships together. We have new technologies coming into our portfolio. We are incredibly active and dynamic in developing commercial and revenue opportunities of significance."

"Could you give us an update on the company's PFAS project?" asked Jolly. "It's a very exciting opportunity," said Calvert. "There is a mandate by the Biden Administration to get this cleaned up. The beauty of this situation is that we got a little bit of a head start before it crescendoed in the market, which means we have the talent and the technical solution advanced sufficiently to be in commercial mode now."

"We would like to be in the field within the next 60-120 days. [PFAS] is a contaminant that has to come out; it is the environmental disaster of the decade," he explained. "We just think this is such an enormous opportunity. We're going to take it from start to finish and prove that it is a commercially viable, economic, and environmentally-friendly solution. Then we're going to partner with companies and take it all over the world."

Calvert then elaborated on the potential customers for this industry, which will likely include the military, municipal, and industrial clients. "Who serves those people? There are really two classes: environmental engineering firms and specialty large companies dedicated to water," explained Calvert. "Both of those are really distributor and partner opportunities for us."

"What is the outlook for your company over the next twelve months?" asked Jolly. "The hardest work is done," said Calvert. "We have never been more excited than today... we have some financing that really provides the resources to get us through this commercial gap," he continued. "I think this is a time where investor enthusiasm is at an all-time high and it will continue. So, we're a company to watch."

"You need to watch carefully, because the evolution of this company is so dynamic that if you're not looking every six months you will only know about half the story," said Calvert. "The hard work is done, the prize is in front of us, let's go do the work and get it done."

To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7875307-biolargo-blgo-discusses-elimination-of-convertible-debt-and-progress-on-commercialization-of-pf

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/


About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.

SOURCE:

Stock Day Media

(602) 821-1102

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/85514

Monday 24 May 2021

BioLargo Strengthens its Balance Sheet by Eliminating Convertible Debt to Position Company for Growth

Westminster, CA – May 24, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced today that it has eliminated nearly all of its convertible debt. The announcement comes as a result of the company having paid off $406,000 in convertible debt that would have come due in August of 2021, through the payment of cash and equity, as reported on Form 8-K filed May 19, 2021. Other than debt owed by its partially owned subsidiary Clyra Medical Technologies, Inc., only Small Business Association and Paycheck Protection Program (PPP) loans totaling $464,000 ($314,000 of which has been applied for forgiveness), and $50,000 of fixed-price convertible debt (due in 2023) remain on BioLargo’s balance sheet.

Dennis P. Calvert, President & CEO of BioLargo discussed the news: “This is quite an accomplishment considering just three years ago we had $7.6 million of debt on our balance sheet. With our financing commitment having over $6 million remaining, we are confident that we can continue to fund our operational needs as we launch our exciting new environmental technologies and grow our revenue.

BioLargo took significant risk three years ago by investing heavily in its environmental platform technologies and the infrastructure to support them, especially its patented low-energy advanced water treatment technology the Advanced Oxidation System (AOS), and the Aqueous Electrostatic Concentrator (AEC), an affordable and eco-friendly solution to treat water contaminated with per- and poly-fluoroalkyl substances (PFAS) (learn more about the worldwide PFAS problem at our blog: https://biolargo.blogspot.com/2021/02/biolargo-answers-administrations-urgent.html). Since that time, the company has advanced both technologies to a point of commercial readiness, with the AOS have already been successfully deployed in several demonstration pilot projects.

BioLargo also made the bold move to form its own engineering company, BioLargo Engineering, Science & Technologies, LLC, located in Oak Ridge, Tennessee. Mr. Calvert commented, “Our engineering division has become a pillar of our company, having played a crucial role in the development and scaling up our AOS and AEC technologies. Our company-wide revenues also have grown significantly, helping make it possible to pay off the debt we used to finance these ambitious development efforts.”

Mr. Calvert ended with, “With this debt behind us, our platform technologies ready for commercial launch, and key industry partnerships taking shape, it’s time to grow our business.”


About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

 

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

 

Thursday 20 May 2021

BioLargo AEC Technology Highlighted as Emerging PFAS Water Treatment Solution in Global Water Intelligence Article

BioLargo’s patented water treatment technology designed for per- and poly-fluoroalkyl substances (PFAS), called the BioLargo Aqueous Electrostatic Concentrator (AEC) is being prepped for its first field demonstration pilots and commercial trials. The technology, which works by using electrolysis to extract PFAS molecules from water and deposit them onto special membranes, boasts better power efficiency, greater specificity for PFAS, extremely high (99.9%+) removal efficiency, and minimal generation of PFAS-laden waste.

Recently our technology was featured in an article by Global Water Intelligence, a leader in market research and technology expertise in the water industry as an “emerging solution” for the PFAS threat. The article, which was in their popular "CTO Roundup Edition", can be found here: https://www.globalwaterintel.com/global-water-intelligence-magazine/22/5/market-map/pfas-treatment-market-concentrates-on-waste-reduction-and-total-destruction 

We are pleased to see our technology being highlighted by recognized thought-leaders in the area of advanced water treatment. As the technology rolls out in its first trials and commercial deployments, articles such as this one will be valuable tools to spread the word about how the BioLargo AEC has the potential to make PFAS treatment more affordable and environmentally friendly everywhere.

Some excerpts from the article include:

“Technology company BioLargo has developed a system that purportedly helps reduce the residuals issue. Its technology exploits the polarity of PFAS molecules, by separating two chambers with a membrane. Each chamber contains an oppositely charged electrode, which pulls the PFAS onto the membrane, where it stays bound. The key benefit to BioLargo’s technology, which is entering the commercial trialling stage, is how little wasted membrane is produced – the company claims it can treat 1 million gallons of water to 70ppt of PFAS with only 12g of membrane material. This produces far less waste for utilities or industrial users to deal with.”

“While sample processing can be expedited by paying a premium for two- to three-day turnaround, laboratories in the US are inundated and there remains a gap in the market for methods of delivering rapid results. “The technology for monitoring PFAS has not developed as fast as the regulations are developing,” observed Tonya Chandler, director of strategic marketing and business development at BioLargo.”

 

Wednesday 19 May 2021

BioLargo CEO says 'hard work is paying off' with balance sheet improvement in its 1Q financials

BioLargo Inc (OTCQB:BLGO) CEO Dennis Calvert tells Proactive the developer of sustainable cleantech technologies that its balance sheet is improving according to its latest financial report.

Calvert says what's more, the California-based company is working with prospective partners to plan and schedule as soon as possible the first commercial pilots for its AEC technology -- which is at the heart of BioLargo’s platform to remove toxic polyfluoroalkyl substances (PFAS) from water.

Monday 17 May 2021

BioLargo Q1 2021 Quarterly Report Highlights Improving Balance Sheet and Status of PFAS Commercial Pilots in Emerging Multi-Billion Dollar Market

 Investor Webcast Scheduled for Wednesday, May 19, 2021 at 4:30pm ET 

Westminster, CA – May 17, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Quarterly Report on Form 10-Q with the SEC today for the three months ended March 31, 2021 (www.biolargo.com/sec-filings). The company has summarized some of the most important points from the report for its investors and provided insights into its strategy for expanding sales of its environmental technologies in existing and new market segments through 2021.

The company also announced an investor webcast to be held on Wednesday, May 19, 2021, at 1:30 pm Pacific / 4:30 pm Eastern, at the following link, open to the public: https://www.webcaster4.com/Webcast/Page/2448/41343

BioLargo investors are also encouraged to attend the company’s online-only Annual Meeting of Stockholders on June 15, 2021, the details of which can be found at www.biolargoreport.com.

Dennis P. Calvert, President and CEO of BioLargo said, “We are now in a strong cash position, have reliable financing resources, and have retired all but $456,000 of our convertible debt. With our financial condition continuing to improve, our team of highly qualified engineers, scientists, and business professionals are uniquely positioned to commercialize our expanding portfolio of innovative environmental technologies, like our AEC system that removes PFAS chemicals from drinking water.”

According to Environmental Business International, the market for PFAS treatment, which BioLargo’s new AEC technology aims to address, will grow to be an $80+ billion market in the US over the next few years, and that there are more than 200 contaminated military sites which urgently require PFAS remediation. Mr. Calvert commented, “Our hard work to develop and commercialize an economical and eco-conscious solution to this huge problem puts us ahead of the curve to address this burgeoning market. Our PFAS remediation technology represents a massive and timely commercial opportunity, with its first commercial pilots starting soon.”

Financial highlights from the 10-Q:

  • Consolidated revenue for the three months ended March 31, 2021 was $571,000, a 30% increase compared to the prior year’s period. 
  • Due in large part to an almost 90% decrease in interest expense as a result of payment and conversion of debt instruments, the company’s net loss for the three months ended March 31, 2021, decreased by 28% as compared to the prior year’s period.
  • In 2021, the company has retired $650,000 in debt. Since December 31, 2019, the company has reduced its debt by over $3.6 million. Other than debt owed by its partially owned subsidiary Clyra Medical, only SBA/PPP loans and fixed-price convertible debt now remain on BioLargo’s balance sheet. Of the fixed price convertible debt, we are currently negotiating the payoff and partial conversion of the $406,000 due in August 2021, and $50,000 is due in two years.
  • As a result of the company’s improved balance sheet, its total stockholder equity is now approximately $772,000. Management expects this trend will be critical to the company as it continues to evaluate the opportunity to uplist its stock to a national stock exchange.

Commercial, operational, and R&D highlights:

  • Established a partnership with Garratt-Callahan, a national industrial water treatment company, to develop and sell custom wastewater treatment and recycling equipment. This dynamic partnership is expanding to include the sales of other BioLargo products and services to Garratt-Callahan customers.
  • The first commercial-scale unit of the company’s Advanced Oxidation System (AOS) water treatment technology began a pilot project at a municipal wastewater treatment plant near Montréal, Québec.
  • BioLargo’s treatment technology for per- and polyfluoroalkyl substances (PFAS) underwent a technical advancement, which was the subject of a recently submitted patent application, that improves the lifespan of the AEC’s membranes and the technology’s overall commercial outlook.
  • The company is working with prospective partners to plan and schedule the first commercial pilots for the AEC technology as soon as possible.
  • BioLargo Engineering’s project backlog grew to a value of over $2 million, to be executed over the next 12-18 months.
  • ONM Environmental added a new air quality control product technology called EcoMist®, a technology that sprays trash bins with odor control product during trash collection.
The commercial-scale AOS being unpacked at the pilot in Montreal


 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday 12 May 2021

BioLargo (BLGO) Q1 2021 Earnings Webcast and Conference Call Wednesday, May 19, 2021 - 4:30 PM Eastern Time

Westminster, CA – May 12, 2021 – BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable clean- technologies and full-service environmental engineering company, will host an investor webcast and conference call on Wednesday May 19, 2021, at 1:30 pm PT / 4:30 pm ET, open to the public. The webcast and conference call will be held to review the company’s financial results, discuss recent company developments, and conduct a question-and-answer session.

The webcast, accompanying presentation materials, and teleconference replay will be made available on the Investor Relations section of BioLargo’s website at biolargo.com/investor-relations.

 

To participate in the live webcast and teleconference:

Webcast Link:

https://www.webcaster4.com/Webcast/Page/2448/41343

Teleconference Domestic:

844-369-8770

Teleconference International:

862-298-0840

 

To watch or listen to a replay of the webcast or teleconference:

 

Webcast Replay Expiration:

Thursday, May 19, 2022

Webcast Link:

https://www.webcaster4.com/Webcast/Page/2448/41343

Teleconference Replay Domestic:

877-481-4010

Teleconference Replay International:

919-882-2331

Replay Passcode:

41343

 

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday 10 May 2021

BioLargo to Present at The Benzinga Global Small Cap Conference on Friday May 14th

Westminster, CA – May 10, 2021– BioLargo, Inc. (OTCQB:BLGO), developer of sustainable clean technologies and a full-service environmental engineering company, announced that it will be presenting at the Benzinga Global Small Cap Conference on Friday May 14, 2021, at 10:10 a.m. Eastern Time. This conference offers a great opportunity for existing and prospective shareholders to learn about BioLargo’s growth prospects in the cleantech and environmental solutions industry. Leaders from around the world are increasingly focused on cleantech as the green energy revolution unfolds globally and the demand for these technologies continues rising.

“Ours is an incredibly dynamic business, and the advancements in our commercial activities in areas like PFAS remediation and water treatment are really shaping our potential for growth as a total cleantech solutions provider,” said BioLargo CEO Dennis P. Calvert. “I am looking forward to talking about these and other new developments in our company. Conferences like the Benzinga Small Cap are integral to our efforts to reach new retail investors and spread the word about BioLargo to new audiences like the cleantech investing community.”  

The Benzinga Global Small Cap conference is free to attend. Register here:  https://www.benzinga.com/events/small-cap/global/

 

About the Benzinga Cleantech Small Cap Conference

The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders. Learn about small cap investing with clearly defined Educational Modules, take a look at a curated group of Small Cap investment opportunities, and connect with the global Small Cap audience in an intimate, virtual setting.  

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BioLargo holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BioLargo has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include without limitation those about BioLargo’s (the “Company”) expectations, anticipated revenue, and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. More information on the risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.